Example 1

Analysis of a Skin Cytoimmunogram from a Healthy Volunteer

How to read indicators of viability, marker composition and marker combinations without mixing up the bases of calculation.

Author: Sergey V. GoltsovPublished: Translated from Russian · Russian originalSection: Experimental Data

In brief

What is shown

  • In the overview sample, the proportion of cells classified as viable by negative 7-AAD staining was 94.0 %.
  • The percentages on each plot are calculated from a separate sample, so values from different samples are not added up to give the cell composition of the biopsy specimen.
  • For each sample, the proportions of the regions and the recalculation within the shown marker-positive population are given, with the denominator stated explicitly.
  • The totals of 99.0 % (CD207 / HLA-DR) and 72.2 % (CD54 / HLA-DR) are incomplete; according to the author’s clarification, this is due to excluded events. The original percentages were not adjusted to 100 %.

Limitations

  • A single case in a volunteer described as healthy does not set reference intervals and does not prove the diagnostic accuracy of the method.
  • The cytometer source files, the full gating scheme and the criteria for excluding events were not provided: the reading of the axes, the correspondence of the regions and the arithmetic of the labels were checked.
  • The phenotypic index of skin inflammation (FIVK) is not calculated from this set of plots.
Key:Source values — numbers from the figures, share of the sampleAuthor’s clarification — the author’s information on this exampleCalculated — recalculation with an explicit denominator

Material and aim of the analysis

The example examines a cell suspension obtained from a skin biopsy specimen of a 42-year-old volunteer described by the author as healthy. Results of flow cytometry in separate samples are presented. The aim of the analysis is to show which characteristics can be extracted from these plots and where the possibilities of their interpretation end.

Author’s clarification Basis of the percentages and the labels on the figures

According to the author’s clarification, the percentages on each plot are calculated from a separate sample. Therefore values from different samples cannot be added up to obtain the overall cell composition of the biopsy specimen.

The coloured annotations on the original illustrations were added later; the numbers below were checked against the figures provided, not against the instrument’s source files.

How a skin cytoimmunogram is obtained and how its report form is structured is described in the article “Skin cytoimmunogram” and in the “Methods” section. In Russian the skin cytoimmunogram is abbreviated ЦИГК.

Viability assessment

In the overview sample, the proportion of cells classified as viable by negative 7-AAD staining was 94.0 %. Low 7-AAD signal is located on the left of the X axis. The positive signal on the right corresponds to cells with impaired membrane integrity [1].

Figure 1. Overview assessment of viability. X axis — 7-AAD, Y axis — side scatter. The labels inside the figure are in Russian. Original illustration by the author.
Text description of the figure

Horizontal axis — 7-AAD staining intensity on a logarithmic scale (axis label “7AAD”); vertical axis — side scatter (label “SS Lin”, from 0 to 1023). A vertical line divides the plot into two parts; the left part carries the label “94,0 %”. Most of the dots lie on the left, in the region of low 7-AAD signal; they are circled with an oval and a callout reading “Viable cells (7-AAD−)” in Russian. On the right, in the region of high signal, there are noticeably fewer dots; this region is circled with an oval and a callout reading “Non-viable cells (7-AAD+)” in Russian.

This indicator characterizes membrane integrity under the conditions of the analysis performed. By itself it does not prove that the material is suitable for cell therapy and does not confirm that all cell functions are preserved.

Side scatter reflects optical properties of cells related to their internal complexity. It does not replace a viability test. On plots without a 7-AAD channel shown, positivity for a cell marker is not independent proof of viability either.

Analysis of the individual samples

Each sample is analysed separately: the plot, the source values of the regions and what can and cannot be read from them. Recalculations of proportions within marker-positive populations are collected in the section “Calculations with explicit denominators”. What the theory calls a subpopulation phenotype is explained in the article “The skin cell subpopulation phenotype”.

Keratinocyte sample: CD49f and HLA-DR

The plot compares CD49f and HLA-DR. CD49f is integrin α6 [2]. In the author’s panel, the CD49f-positive population is designated as keratinocytes. To read the percentages presented, both CD49f-positive regions must be taken into account, not only the region without HLA-DR.

Figure 2. CD49f on the X axis and HLA-DR on the Y axis. The percentages refer to a separate sample. Original illustration by the author.
Text description of the figure

Horizontal axis — CD49f-PE, vertical axis — HLA-DR-PC7, both on a logarithmic scale. Two lines divide the plot into four regions. Upper left, B1 (CD49f− HLA-DR+) — 1.3 %, only a few dots. Upper right, B2 (CD49f+ HLA-DR+) — 41.4 %, a broad cloud of dots. Lower left, B3 (CD49f− HLA-DR−) — 3.1 %, a small cluster near the vertical boundary. Lower right, B4 (CD49f+ HLA-DR−) — 54.2 %, the densest cloud. Decimal commas are used in the figure.

Source values Figure 2, share of the sample

Phenotype Region Share of the sample
CD49f− HLA-DR+ B1 1.3 %
CD49f+ HLA-DR+ B2 41.4 %
CD49f− HLA-DR− B3 3.1 %
CD49f+ HLA-DR− B4 54.2 %

The region negative for both markers, 3.1 %, is not equivalent to non-viable cells or debris.

Within the author’s panel, HLA-DR is regarded as a sign of activation. This plot describes a combination of markers; without additional data it does not establish the cause of their expression, the presence of a disease, the effect of a drug or the intensity of regeneration.

Fibroblast sample: CD44 and CD80

In the original description, the fibroblast population is defined by the combination CD45− CD14− CD44+. Only CD44 and CD80 are shown on the plot provided. The full sequence of preliminary gating of the population is not presented in the material provided.

Figure 3. CD80 on the X axis and CD44 on the Y axis. The region labels and numerical labels are retained from the original illustration. Original illustration by the author.
Text description of the figure

Horizontal axis — CD80-FITC, vertical axis — CD44-PE, both on a logarithmic scale. Upper left, N1 (CD44+ CD80−) — 86.0 %, the main dense cloud of dots. Upper right, N2 (CD44+ CD80+) — 6.2 %, a smaller cloud to the right of the vertical boundary. Lower left, N3 (CD44− CD80−) — 6.7 %. Lower right, N4 (CD44− CD80+) — 1.1 %, sparse dots.

Source values Figure 3, share of the sample

Phenotype on the plot Region Share of the sample
CD44+ CD80− N1 86.0 %
CD44+ CD80+ N2 6.2 %
CD44− CD80− N3 6.7 %
CD44− CD80+ N4 1.1 %

A separate 7-AAD plot in the original document contains a viability value of 86.0 %. The coincidence of this number with the CD44+ CD80− proportion in another sample does not make the values identical. The proportion of viable cells and the proportion of marker-positive events are considered separately here, because they were obtained in different samples.

The data presented make it possible to describe the distribution of markers in this sample. Conclusions about functional potential, tissue repair or treatment effectiveness would require independent grounds.

CD249-positive sample: CD249 and CD63

Author’s clarification Marker used

The author confirmed that CD249 was used. The designation has therefore been kept.

However, CD249 is not c-Kit/SCFR: CD249 corresponds to ENPEP, whereas c-Kit/SCFR is CD117 [3], [4]. This analysis uses the precise description “a CD249-positive population designated by the author as mast cells”. This plot alone is not sufficient for an independent check of its cellular identity.

Source values Original illustration by the author, share of the sample (the plot is not included in this analysis)

Phenotype Share of the sample
CD249+ CD63− 6.8 %
CD249+ CD63+ 1.1 %
CD249− CD63− 83.5 %
CD249− CD63+ 8.6 %

The value 6.8 % describes only the CD249+ CD63− region and is not a viability indicator.

Monocyte sample: CD45 and HLA-DR

In the author’s panel, monocytes are designated as CD45+ CD14+. The plot provided shows CD45 on the Y axis and HLA-DR on the X axis; the CD14 channel and the preliminary gating of CD14+ events are not shown.

Source values Original illustration by the author, share of the sample (the plot is not included in this analysis)

Phenotype on the plot Share of the sample
CD45+ HLA-DR− 7.0 %
CD45+ HLA-DR+ 2.6 %
CD45− HLA-DR− 79.4 %
CD45− HLA-DR+ 11.0 %

The value 7.0 % refers to the CD45+ HLA-DR− region and does not characterize viability.

These values do not establish the presence or absence of infection, allergy or other diseases and do not allow the result of therapy to be assessed without additional data.

CD207-positive sample: CD207 and HLA-DR

The author designates the population under study as intraepidermal macrophages. The plot shows CD207-APC on the X axis and HLA-DR-PC7 on the Y axis. CD207-positive events lie to the right of the vertical boundary.

Figure 4. Fragment of the original plot. X axis — CD207-APC, Y axis — HLA-DR-PC7. The dots and numerical labels are retained; the external annotations are not shown. Illustration by the author, cropped.
Text description of the figure

Horizontal axis — CD207-APC, vertical axis — HLA-DR (the axis title is outside the crop), both on a logarithmic scale. Upper left, S1 — 47.9 %; upper right, S2 — 4.9 %; lower left, S3 — 46.1 %; lower right, S4 — 0.1 %. The main cloud of dots lies to the left of the vertical boundary and crosses the horizontal one; to the right of the vertical boundary there is a separate small cluster in the upper right region. The ovals and arrow tips are parts of the original annotations; the annotations themselves are cropped out.

Source values Figure 4, share of the sample

Phenotype Region Share of the sample
CD207− HLA-DR+ S1 47.9 %
CD207+ HLA-DR+ S2 4.9 %
CD207− HLA-DR− S3 46.1 %
CD207+ HLA-DR− S4 0.1 %
Total of the four regions 99.0 %

Author’s clarification Incomplete total of 99.0 %

The four regions shown add up to 99.0 %. According to the author’s clarification, the incomplete total is due to excluded events.

The original percentages have been kept without adjusting the total to 100 %. The exclusion criteria are not described in the material provided.

The value 47.9 % refers to the CD207− HLA-DR+ region, and 0.1 % to the CD207+ HLA-DR− region. They cannot be described, respectively, as the total number of CD207+ cells and the activated part of this population.

CD54 and HLA-DR sample

In the original document this sample is assigned to the endothelial CD146+ population. The plot itself shows CD54 and HLA-DR; the CD146 channel and the step of preliminary gating of the population are not visible here. The numerical analysis below therefore refers directly to the regions shown.

Figure 5. Fragment of the original CD54 / HLA-DR plot. The external annotations and the summary infographic below it are not shown. Illustration by the author, cropped.
Text description of the figure

Horizontal axis — CD54-FITC, vertical axis — HLA-DR-PC7, both on a logarithmic scale. Upper left, B1 — 5.4 %; upper right, B2 — 5.9 %; lower left, B3 — 0.6 %; lower right, B4 — 60.3 %, where the densest cloud of dots lies. Arrow tips of the original annotations are visible at the edges; the annotations themselves are cropped out.

Source values Figure 5, share of the sample

Phenotype Region Share of the sample
CD54− HLA-DR+ B1 5.4 %
CD54+ HLA-DR+ B2 5.9 %
CD54− HLA-DR− B3 0.6 %
CD54+ HLA-DR− B4 60.3 %
Total of the four regions 72.2 %

Author’s clarification Incomplete total of 72.2 %

The total of the four regions is 72.2 %. According to the author’s clarification, the incomplete total is due to excluded events.

The remaining 27.8 percentage points are not redistributed among the regions shown and are not designated as any particular cell type. The value 60.3 % refers to CD54+ HLA-DR− events.

Without the event selection scheme shown, the total of 72.2 % cannot be independently confirmed as the proportion of all viable endothelial cells in the original biopsy specimen.

Calculations with explicit denominators

One rule applies to all samples: first the proportion of the sample is stated, then, if necessary, it is recalculated relative to the parent population shown. Such a recalculation is an arithmetic characteristic of the plot, not a new measurement. The calculations use the rounded labels of the figures; the results of the recalculations are rounded to one decimal place.

Calculated Summary of recalculations

Sample Denominator — positive regions shown, % of the sample Numerator, % of the sample Proportion within the denominator
CD49f / HLA-DR CD49f+: 41.4 + 54.2 = 95.6 CD49f+ HLA-DR+: 41.4 ≈ 43.3 %
CD44 / CD80 CD44+: 86.0 + 6.2 = 92.2 CD44+ CD80+: 6.2 ≈ 6.7 %
CD249 / CD63 CD249+: 6.8 + 1.1 = 7.9 CD249+ CD63+: 1.1 ≈ 13.9 %
CD45 / HLA-DR CD45+: 7.0 + 2.6 = 9.6 CD45+ HLA-DR+: 2.6 ≈ 27.1 %
CD207 / HLA-DR CD207+: 4.9 + 0.1 = 5.0 CD207+ HLA-DR+: 4.9 98.0 %

Keratinocyte sample

Calculated Denominator — all CD49f+ events shown (B2 + B4)

CD49f+ = 41.4 + 54.2 = 95.6 % of the sample

CD49f+ HLA-DR+ within CD49f+ = 41.4 / 95.6 × 100 ≈ 43.3 %

The total proportion of CD49f+ events is 95.6 % of this sample. Double positivity CD49f+ HLA-DR+ is 41.4 % of the sample and about 43.3 % within the CD49f+ population presented.

Thus “41.4 % of the sample” and “43.3 % of the CD49f+ population” describe the same events with different denominators.

Fibroblast sample

Calculated Denominator — CD44+ events shown (N1 + N2)

CD44+ = 86.0 + 6.2 = 92.2 % of the sample

CD80+ within CD44+ = 6.2 / 92.2 × 100 ≈ 6.7 %

In the author’s panel, this combination is used to characterize the activated part of the population.

CD249-positive sample

Calculated Denominator — CD249+ events shown

CD249+ = 6.8 + 1.1 = 7.9 % of the sample

CD249+ CD63+ within CD249+ = 1.1 / 7.9 × 100 ≈ 13.9 %

CD249+ CD63+ events make up 1.1 % of the sample, or about 13.9 % of the CD249+ population presented.

Monocyte sample

Calculated Denominator — CD45+ events shown

CD45+ = 7.0 + 2.6 = 9.6 % of the sample

CD45+ HLA-DR+ within CD45+ = 2.6 / 9.6 × 100 ≈ 27.1 %

Double positivity CD45+ HLA-DR+ is 2.6 % of the sample, or about 27.1 % of the CD45+ population presented.

CD207-positive sample

Calculated Denominator — CD207+ events shown (S2 + S4)

CD207+ = 4.9 + 0.1 = 5.0 % of the sample

HLA-DR+ among CD207+ = 4.9 / 5.0 × 100 = 98.0 %

This is a calculation based on the rounded labels of the figure. The calculated proportion of HLA-DR+ does not by itself establish pathological activation.

CD54 and HLA-DR sample

Calculated Denominator — the whole sample (the regions shown total 72.2 %)

at least one positive marker = 5.4 + 5.9 + 60.3 = 71.6 % of the sample

double positivity CD54+ HLA-DR+ = 5.9 % of the sample

region negative for both markers = 0.6 % of the sample

Calculated Additional recalculation: denominator — only the four regions shown (72.2 %)

Region Phenotype Share of the sample Share within 72.2 %
B4 CD54+ HLA-DR− 60.3 % 83.5 %
B1 CD54− HLA-DR+ 5.4 % 7.5 %
B2 CD54+ HLA-DR+ 5.9 % 8.2 %
B3 CD54− HLA-DR− 0.6 % 0.8 %

This additional recalculation does not replace the original percentages of the sample.

Interpretation and limitations

The example illustrates three different levels of description: viability by 7-AAD, the distribution of cell markers in separate samples, and the calculation of proportions within the marker-positive populations shown. Separating these levels makes the result clearer and prevents erroneous conclusions from coinciding or incomparable percentages.

In Phenotypic Dermatology, such measurements may characterize individual components of the skin state S(x, t). At the same time, the plots do not fully describe the interactions of subpopulations and tissue organization. To link the result to S(x, t), information about the skin site x and the time point t of the study is needed.

Note Limitations

A single case in a volunteer described as healthy does not set reference intervals and does not prove the diagnostic accuracy of the method. There are no repeated observations, so this example also does not demonstrate a transition between skin states or a treatment result.

The phenotypic index of skin inflammation (FIVK, the Latin transliteration of the Russian abbreviation ФИВК) is not calculated from the set of plots presented.

Limits of the check

The illustrations and text of the author’s example are available. The cytometer source files, the full gating scheme, the criteria for excluding events, the total number of recorded events and the absolute cell concentration were not provided. Therefore the reading of the axes, the correspondence of the regions and the arithmetic of the labels were checked; the original measurements were not reprocessed. The results of the recalculations are rounded to one decimal place.

Further reading

Sources and data provenance

Case data: the author’s file “Пример 1.docx” [Example 1], figures and description. The author’s clarifications of 21.11.2026: percentages are calculated from a separate sample; the labels were added later; CD249 was used; the incomplete totals are due to excluded events. These clarifications are not attributed to previously published sources.

Translated from Russian. Numbers are given with decimal points; the figures themselves use decimal commas.

  1. Thermo Fisher Scientific — 7-AAD and membrane integrity (opens in a new tab)
  2. Thermo Fisher Scientific — CD49f / integrin α6 (opens in a new tab)
  3. Human Protein Atlas — ENPEP / CD249 (opens in a new tab)
  4. BD Biosciences — CD117 / c-Kit / SCFR, technical data sheet, p. 1 (opens in a new tab)

The reference sources were checked on 21.11.2026. They confirm the properties of the dye and the designations of the molecules, but not the actual reagent panel or the results of the experiment under discussion.

Case data source — S17 (the author’s file “Пример 1.docx” [Example 1] and the author’s clarifications of 21.11.2026); reference information on markers — S18–S21. Translated from Russian; the translation has not been reviewed by the author.

This material is for information only and does not replace a consultation with a doctor.

← All materials in “Experimental Data”